Cooley advised Impact Therapeutics on the deal. Impact Therapeutics and Eikon Therapeutics announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here